Arabic Arabic English English French French German German
dark

Biogen calls criticism of Alzheimer’s drug ‘misinformation’

Biogen Inc. fought back against criticism of the unusual circumstances that led to the U.S. approval of its Alzheimer’s drug Aduhelm, saying in an open letter it has been the subject of “extensive misinformation and misunderstanding.” Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Hyperoside protects against heart failure-induced liver fibrosis.

Next Post

Hyperoside attenuates renal aging and injury induced by D-galactose.

Related Posts
Total
0
Share